Current Urology Reports

, 9:113 | Cite as

Current status of high-intensity focused ultrasound for prostate cancer: Technology, clinical outcomes, and future



Based on a review of recently published articles, we evaluated the current status of high-intensity focused ultrasound (HIFU) as a primary treatment option for localized prostate cancer and as a salvage therapy when radiation has failed. With mid-and long-term progression-free survival rates around 70%, negative postoperative prostate biopsies almost 90%, and an excellent morbidity profile, primary HIFU appears to be a valid alternative to active surveillance protocols in low-risk patients and standard therapies in patients with life expectancies of 10 or fewer years. Moreover, HIFU has a considerable potential for local-only recurrence after radiation failure. HIFU is a recent technology, and many improvements will undoubtedly expand its future indications and use for the management of prostate cancer.

References and Recommended Reading

  1. 1.
    Sim HG, Cheng CW: Changing demography of prostate cancer in Asia. Eur J Cancer 2005, 41:834–845.PubMedCrossRefGoogle Scholar
  2. 2.
    Grönberg H: Prostate cancer epidemiology. Lancet 2003, 361:859–864.PubMedCrossRefGoogle Scholar
  3. 3.
    Boccon-Gibod LM, Dumonceau O, Toublang M, et al.: Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Eur Urol 2005, 48:895–899.PubMedCrossRefGoogle Scholar
  4. 4.
    Adolfsson J, Tribukait B, Levitt S: The 20-yr outcome in patients with well-or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumor ploidy and comorbidity. Eur Urol 2007, 52:1028–1035.PubMedCrossRefGoogle Scholar
  5. 5.
    Wong YN, Mitra N, Hudes G, et al.: Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006, 296:2683–2693.PubMedCrossRefGoogle Scholar
  6. 6.
    Ter Haar G, Coussios C: High intensity focused ultrasound: physical principles and devices. Int J Hyperthermia 2007, 23:89–104.PubMedCrossRefGoogle Scholar
  7. 7.
    Chapelon JY, Margonari J, Vernier F, et al.: In vivo effects of high-intensity ultrasound on prostate adenocarcinoma Dunning R3327. Cancer Res 1992, 52:6353–6357.PubMedGoogle Scholar
  8. 8.
    Rouviere O, Lyonnet D, Raudrant A, et al.: MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 2001, 40:265–274.PubMedCrossRefGoogle Scholar
  9. 9.
    Rouviere O, Souchon R, Salomir R, et al.: Transrectal high-intensity focused ultrasound ablation of prostate cancer: Effective treatment requiring accurate imaging. Eur J Radiol 2007, 63:317–327.PubMedCrossRefGoogle Scholar
  10. 10.
    De Senneville BD, Mougenot C, Moonen CT: Real-time methods for treatment of mobile organs by MRI-controlled high-intensity focused ultrasound. Magn Reson Med 2007, 57:319–330.PubMedCrossRefGoogle Scholar
  11. 11.
    Illing RO, Leslie TA, Kennedy JE, et al.: Visually directed high-intensity focused ultrasound for organ-confined prostate cancer: a proposed standard for the conduct of therapy. BJU Int 2006, 98:1187–1192.PubMedCrossRefGoogle Scholar
  12. 12.
    Ficarra V, Antoniolli SZ, Novara G, et al.: Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int 2006, 98:1193–1198.PubMedCrossRefGoogle Scholar
  13. 13.
    Uchida T, Ohkusa H, Nagata Y, et al.: Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 2006, 97:56–61.PubMedCrossRefGoogle Scholar
  14. 14.
    Blana A, Walter B, Rogenhofer S, Wieland WF: High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004, 63:297–300.PubMedCrossRefGoogle Scholar
  15. 15.
    Chaussy C, Thuroff S: The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 2003, 4:248–252.PubMedCrossRefGoogle Scholar
  16. 16.
    Lee HM, Hong JH, Choi HY: High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 2006, 9:439–443.PubMedCrossRefGoogle Scholar
  17. 17.
    Poissonnier L, Chapelon JY, Rouviere O, et al.: Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007, 51:381–387.PubMedCrossRefGoogle Scholar
  18. 18.
    Vallancien G, Prapotnich D, Cathelineau X, et al.: Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 2004, 171:2265–2267.PubMedCrossRefGoogle Scholar
  19. 19.
    Thuroff S, Chaussy C, Vallancien G, et al.: High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 2003, 17:673–677.PubMedCrossRefGoogle Scholar
  20. 20.
    Uchida T, Ohkusa H, Yamashita H, et al.: Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 2006, 13:228–233.PubMedCrossRefGoogle Scholar
  21. 21.
    Uchida T, Illing RO, Cathcart PJ, Emberton M: To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 2006, 98:537–539.PubMedCrossRefGoogle Scholar
  22. 22.
    Uchida T, Rowland O, Cathcart PJ, Emberton M: The effect of neoadjuvant androgen suppression on prostate-related outcomes after high-intensity focused ultrasound. BJU Int 2006, 98:770–772.PubMedCrossRefGoogle Scholar
  23. 23.
    Blana A, Murat FJ, Walter B, et al.: First analysis of the long-term results with transrectal HIFU in patients with localized prostate cancer. Eur Urol 2007, In press.Google Scholar
  24. 24.
    Rebillard X, Davin JL, Soulie M, Comite de cancerologie de l’Association Francaise d’Urologie: Treatment by HIFU of prostate cancer: survey of literature and treatment indications. Prog Urol 2003, 13:1428–1456.PubMedGoogle Scholar
  25. 25.
    Madersbacher S, Pedevilla M, Vingers L, et al.: Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995, 55:3346–3351.PubMedGoogle Scholar
  26. 26.
    Gelet A, Chapelon JY, Bouvier R, et al.: Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol 1996, 29:174–183.PubMedGoogle Scholar
  27. 26.
    Chaussy C, Thuroff S: Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J Endourol 2001, 15:437–440.PubMedCrossRefGoogle Scholar
  28. 27.
    Ganzer R, Rogenhofer S, Walter B, et al.: PSA nadir is a significant predictor of treatment failure after high intensity focused ultrasound (HIFU) treatment of localized prostate cancer. Eur Urol, 2007, In press.Google Scholar
  29. 28.
    Gelet A, Chapelon JY, Bouvier R, et al.: Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol 2001, 40:124–129.PubMedCrossRefGoogle Scholar
  30. 29.
    Chaussy C, Thuroff S: High-intensity focused ultrasound in localized prostate cancer. J Endourol 2000, 14:293–299.PubMedCrossRefGoogle Scholar
  31. 30.
    Thuroff S, Chaussy C: High-intensity focused ultrasound: complications and adverse effects. Mol Urol 2000, 4:183–187.PubMedGoogle Scholar
  32. 31.
    Chaussy C, Thuroff S, Rebillard X, Gelet A: Technology insight: high intensity focused ultrasound for urologic cancers. Nat Clin Pract Urol 2005, 2:191–198.PubMedCrossRefGoogle Scholar
  33. 32.
    Blana A, Rogenhofer S, Ganzer R, et al.: Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 2006, 24:585–590.PubMedCrossRefGoogle Scholar
  34. 33.
    Pollack A, Hanlon AL, Horwitz EM, et al.: Prostate cancer radiotherapy dose response: an update of the Fox Chase experience. J Urol 2004, 171:1132–1136.PubMedCrossRefGoogle Scholar
  35. 34.
    Shipley WU, Thames HD, Sandler HM, et al.: Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999, 281:1598–1604.PubMedCrossRefGoogle Scholar
  36. 35.
    Zelefsky MJ, Kuban DA, Levy LB, et al.: Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2005, 62:327–333.Google Scholar
  37. 36.
    Heinish M, Dirisamer A, Loidl W, et al.: Positron emission tomography/computed tomography with F-18-Fluorcholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 2006, 8:43–48.CrossRefGoogle Scholar
  38. 37.
    Harisinghani MG, Barentsz J, Hahn PF, et al.: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348:2491–2499.PubMedCrossRefGoogle Scholar
  39. 38.
    Chaussy C, Thuroff S, Bergsdorf T: Local recurrence of prostate cancer after curative therapy. HIFU (Ablatherm) as a treatment option [in German]. Urologe 2006, 45:1271–1275.PubMedCrossRefGoogle Scholar
  40. 39.
    Murat FJ, Poissonnier L, Rouviere O, et al.: Salvage high intensity focused ultrasound (HIFU) treatment for recurrent prostate cancer after radiation therapy: High efficacy in patients with good initial prognosis [abstract 1777]. J Urol 2007, 177:591.Google Scholar
  41. 40.
    Ross AB, Diederich CJ, Nau WH, et al.: Curvilinear transurethral ultrasound applicator for selective prostate thermal therapy. Med Phys 2005, 32:1555–1565.PubMedCrossRefGoogle Scholar
  42. 41.
    Piel JE, Watkins RD, Gross P, et al.: A transrectal focused ultrasound probe for MR-guided ablation of the prostate. Proceedings of the 13th scientific meeting of the international society for magnetic resonance in medicine. Miami: International Society for Magnetic Resonance in Medicine; 2005.Google Scholar
  43. 42.
    Paparel P, Curiel L, Chesnais S, et al.: Synergistic inhibitory effect of high-intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma. BJU Int 2005, 95:881–885.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Urology and Transplantation DepartmentEdouard Herriot HospitalLyon Cedex 03France

Personalised recommendations